Genta announces preliminary results from study of Genasense Injection for advanced melanoma

20. November 2009 09:02

Genta Incorporated announced preliminary results that show a high objective response rate in a pilot study of patients with advanced melanoma that incorporates the Company’s lead oncology product, Genasense® (oblimersen sodium) Injection, administered for the first time as a 1-hour high-dose intravenous (IV) infusion. [More]

4860eda6-fe31-4d8b-a8a6-7cc875daf80d|0|.0

Posted in: Drug Trial News | Medical Condition News

Tags: Abraxane, Apoptosis, Bone, Cancer, Cell, Chemotherapy, Dacarbazine, DNA, Docetaxel, Evolution, Melanoma, Neutropenia, Oncology, Paclitaxel, Skin Cancer, Temozolomide

Aegera Therapeutics commences AEG35156 Phase 2B study for AML

19. November 2009 10:37

Aegera Therapeutics Inc. announced today the dosing of the first patient in a randomized Phase 2B study of AEG35156, a targeted antisense therapeutic in mid-stage development for multiple oncology indications. [More]

0f477df3-7276-483a-9f16-5c5e959136a1|0|.0

Posted in: Drug Trial News | Medical Condition News

Tags: Antisense, Apoptosis, Biotechnology, Cancer, Cell, Chemotherapy, Hepatocellular Carcinoma, Leukemia, Lymphoma, Oncology, Sorafenib

Study: EP4 agonist may reduce gastric bleeding and inflammation

19. November 2009 03:46

Over 300 million patients use non-steroidal anti-inflammatory drugs (NSAIDs) in the world to treat pain, arthritis, fever and other diseases. Nearly 30% of the users suffer from gastric lesions and bleeding. [More]

7960f209-1487-488b-96eb-89e0354e0e77|0|.0

Posted in: Medical Science News | Pharmaceutical News

Tags: Anti-Inflammatory, Apoptosis, Arthritis, Cancer, Cell, Colorectal Cancer, Esophageal Cancer, Gastroenterology, Hepatology, Indomethacin, Liver Cancer, Ulcer

New data on Synta Pharmaceuticals' elesclomol presented at the AACR-NCI-EORTC Conference

18. November 2009 09:08

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today presented new data on the mechanism of action of elesclomol, a first-in-class oxidative stress inducer, at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics in Boston, Mass. [More]

36558819-deb9-4922-bb20-43e281a8e1fc|0|.0

Posted in: Medical Condition News | Pharmaceutical News

Tags: Apoptosis, Cancer, Cell, Chemotherapy, Copper, Hematology, Melanoma, Oxidative Stress, Paclitaxel, Stress

Data on Synta Pharmaceuticals' STA-9090 synthetic inhibitor of Hsp90 presented

18. November 2009 08:40

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical data presented at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics shows that STA-9090, a novel, synthetic inhibitor of heat shock protein 90 (Hsp90), demonstrated strong activity in multiple tumor models. [More]

7105e9d6-13ab-4fd4-afa9-3e55eccba03a|0|.0

Posted in: Drug Trial News | Medical Condition News

Tags: Acute Lymphoblastic Leukemia, Apoptosis, Breast Cancer, Cancer, Cell, Chronic Myeloid Leukemia, Colon Cancer, Erlotinib, Gleevec, Hospital, Leukemia, Lung Cancer, Lymphoma, Melanoma, Multiple Myeloma, Myeloid Leukemia, Non-Small Cell Lung Cancer, Oncology, Paclitaxel, Pancreatic Cancer, Prostate Cancer, Small Cell Lung Cancer, Sunitinib, Tarceva, Xenograft

Cancer-fighting protein successfully placed directly into solid tumors and turned on

18. November 2009 05:58

Experiments at the Pioneer Valley Life Sciences Institute (PVLSI) at Baystate Medical Center in Springfield, Mass., reported in a recent British Journal of Cancer, confirm that University of Massachusetts Amherst chemical engineer Neil Forbes' delivery and trigger system has for the first time successfully placed TRAIL, a cancer-fighting protein, directly into solid tumors and on cue, turned it on. The treatment improved the 30-day survival time of mice with mammary tumors from 0 to 100 percent. [More]

d9a70f40-3bd8-4eec-bcbc-add2bfb8d143|0|.0

Posted in: Medical Science News | Medical Condition News

Tags: Apoptosis, Breast Cancer, Cancer, Cell, DNA, Oncology, Salmonella

First-quarter fiscal 2010 results announced by Senesco Technologies

17. November 2009 09:04

Senesco Technologies, Inc. today reported financial results for the three months ended September 30, 2009. [More]

55e71b96-6bc1-4607-a5ce-493ade991843|0|.0

Posted in: Business / Finance

Tags: Apoptosis, Biotechnology, Cancer, Cell, Multiple Myeloma, Oncology, Stress

Melanoma Institute director to present Phase 2 study data of PV-10 for metastatic melanoma

17. November 2009 08:04

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that Professor John F. Thompson, MD, Professor of Melanoma and Surgical Oncology at the University of Sydney, Director of the Melanoma Institute Australia, and Lead Investigator of the Phase 2 study of PV-10 for Metastatic Melanoma, will be presenting data at the 3rd World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers on November 21, 2009 in Berlin, Germany. [More]

1e4e8117-84c9-490f-b3e0-d09c1aace944|0|.0

Posted in: Drug Trial News | Medical Condition News

Tags: Apoptosis, Atopic Dermatitis, Breast Cancer, Cancer, Cell, Dermatitis, Dermatology, Evolution, Liver Cancer, Melanoma, Metastasis, Oncology, Psoriasis, Skin Cancer

New insights into cells' reaction to DNA damage

17. November 2009 04:55

Cancer researchers of the Max Delbr-ck Center for Molecular Medicine (MDC) Berlin-Buch have gained new insights into how cells react to DNA damage. Dr. Michael Stilmann, Dr. Michael Hinz and Professor Claus Scheidereit have shown that the protein PARP-1, which detects DNA damage within seconds, activates the transcription factor NF-kappaB, a well-known regulator of gene expression. [More]

b9b0d584-ce87-4f38-b400-2cdfb018f946|0|.0

Posted in: Medical Science News

Tags: Apoptosis, Cancer, Cell, DNA, Gene Expression, Hodgkin's Lymphoma, Lymphoma, Radiation Therapy

Interim data from Hollis-Eden Pharmaceuticals' Apoptone Phase I/II clinical trial presented

16. November 2009 10:21

Hollis-Eden Pharmaceuticals, Inc., today reported preliminary results of its ongoing Phase I/II clinical trial with Apoptone® (HE3235) for hormone-resistant prostate cancer (also called castrate-resistant prostate cancer or CRPC). Presented at the Molecular Targets and Cancer Therapeutics Conference, which is co-sponsored by the AACR, NCI and EORTC, the poster is titled: "Results of preclinical and clinical Phase I/II open-label dose-ranging trial with HE3235, a synthetic adrenal hormone, in Castrate Resistant Prostate Cancer (CRPC)." [More]

ff0dced7-006e-4a03-a98a-cf8c7f078101|0|.0

Posted in: Men's Health News | Drug Trial News

Tags: Apoptosis, Bone, Cancer, Cell, Cell Proliferation, Chemotherapy, Diabetes, Diabetes Mellitus, Dihydrotestosterone, Oncology, Prostate Cancer, Steroid, Type 2 Diabetes

FDA issues a Complete Response Letter for Human Genome Sciences' raxibacumab BLA

16. November 2009 07:53

Human Genome Sciences, Inc. today announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) relating to the Company’s Biologics License Application (BLA) requesting the approval of raxibacumab for use in the treatment of inhalational anthrax. The FDA issues Complete Response Letters to request additional information needed to complete the review of a BLA. [More]

3188a212-2b6e-433f-a59c-a41d46de3d12|0|.0

Posted in: Disease/Infection News | Pharmaceutical News

Tags: Anthrax, Antibody, Apoptosis, Cancer, Cell, Coronary Heart Disease, Diabetes, Health and Human Services, Hepatitis C, Lupus, Systemic Lupus Erythematosus

According to new research lipid that accumulates in brain cells drives cell death

13. November 2009 04:32

The lipid that accumulates in brain cells of individuals with an inherited enzyme disorder also drives the cell death that is a hallmark of the disease, according to new research led by St. Jude Children's Research Hospital investigators. [More]

7501fbda-21c9-4921-9a80-48c8acc10ef9|0|.0

Posted in: Medical Science News | Medical Condition News

Tags: Apoptosis, Brain, Calcium, Cancer, Cell, Gene Therapy, Genetics, Hospital, Lipids, Neurodegeneration, Protein Folding

Senesco Technologies to present data on its multiple myeloma drug candidate at the AACR-NCI-EORTC conference

12. November 2009 11:00

Senesco Technologies, Inc. announced today that Catherine Taylor, one of the Company's funded researchers, will be presenting pre-clinical stability and biological activity data on SNS-01, Senesco's multiple myeloma drug candidate, at the 2009 American Association for Cancer Research (AACR)-National Cancer Institute (NCI)-European Organization for Research and Treatment of Cancer (EORTC) Molecular Targets and Cancer Therapeutics Conference. [More]

fed0db4a-35ab-4f99-b105-245df7e8e54e|0|.0

Posted in: Drug Trial News | Medical Condition News

Tags: Apoptosis, Biotechnology, Cancer, Cell, Multiple Myeloma, Stress

Potential new drug for lung cancer eliminates tumors in mice

11. November 2009 00:24

A potential new drug for lung cancer has eliminated tumours in 50% of mice in a new study published today in the journal Cancer Research. In the animals, the drug also stopped lung cancer tumours from growing and becoming resistant to treatment. The authors of the research, from Imperial College London, are now planning to take the drug into clinical trials, to establish whether it could offer hope to patients with an inoperable form of lung cancer. [More]

2a9c5c1b-a300-4337-9787-61d952dfe335|0|.0

Posted in: Medical Science News | Medical Condition News

Tags: Apoptosis, Cancer, Cell, Cell Proliferation, Chemotherapy, Cisplatin, DNA, Growth Hormone, Lung Cancer, Oncology, Radiotherapy, Small Cell Lung Cancer

EpiCept announces third quarter 2009 financial results

10. November 2009 00:45

EpiCept Corporation today announced operating and financial results for the three and nine months ended September 30, 2009, and provided an update on Ceplene® and several of the Company’s key product candidates. [More]

84e877a4-3312-4b4a-8cb7-dbd6b5658da1|0|.0

Posted in: Business / Finance

Tags: Apoptosis, Bone, Bone Marrow, Bone Marrow Disease, Cancer, Cell, Evolution, Exercise, Gabapentin, Genetics, Histamine, Interleukin-2, Leukemia, Myeloid Leukemia, Neuralgia, New Drug Application, Oncology, Pharmacology

Free!

Recent Comments

Twitter

Information

Apoptosis News and Research

Genta announces preliminary results from study of Genasense Injection for advanced melanoma

Aegera Therapeutics commences AEG35156 Phase 2B study for AML

Study: EP4 agonist may reduce gastric bleeding and inflammation

New data on Synta Pharmaceuticals' elesclomol presented at the AACR-NCI-EORTC Conference

Data on Synta Pharmaceuticals' STA-9090 synthetic inhibitor of Hsp90 presented

Cancer-fighting protein successfully placed directly into solid tumors and turned on

First-quarter fiscal 2010 results announced by Senesco Technologies

Melanoma Institute director to present Phase 2 study data of PV-10 for metastatic melanoma

New insights into cells' reaction to DNA damage

Interim data from Hollis-Eden Pharmaceuticals' Apoptone Phase I/II clinical trial presented

FDA issues a Complete Response Letter for Human Genome Sciences' raxibacumab BLA

According to new research lipid that accumulates in brain cells drives cell death

Senesco Technologies to present data on its multiple myeloma drug candidate at the AACR-NCI-EORTC conference

Potential new drug for lung cancer eliminates tumors in mice

EpiCept announces third quarter 2009 financial results

Recent Articles

Free!

Recent Comments

Twitter

Information

Apoptosis News and Research

Medical News Cloud

Recent Articles